These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29429368)

  • 1. Effects of statins on all-cause mortality at different low-density-lipoprotein cholesterol levels in Asian patients with type 2 diabetes.
    Chen PH; Wang JS; Lin SY; Li CH; Wang CY; Hu CY; Fu CP; Tsai YT; Lee AT; Chen YW; Li YH; Lee CL
    Curr Med Res Opin; 2018 Nov; 34(11):1885-1892. PubMed ID: 29429368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study.
    Fung CSC; Wan EYF; Chan AKC; Lam CLK
    BMC Cardiovasc Disord; 2017 Jun; 17(1):166. PubMed ID: 28645252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin Therapy in Patients With Low Serum Levels of Low-Density Lipoprotein Cholesterol.
    Tsujimoto T; Kajio H; Sugiyama T
    Am J Cardiol; 2017 Dec; 120(11):1947-1954. PubMed ID: 28951019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
    J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
    Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.
    Hasegawa Y; Hori M; Nakagami T; Harada-Shiba M; Uchigata Y
    J Clin Lipidol; 2018; 12(1):62-69.e1. PubMed ID: 29217412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sodium-glucose cotransporter 2 inhibitors on serum low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus.
    Imada T; Katakami N; Watanabe H; Nishina S; Sasaki S; Takahara M; Shimomura I; Yamamoto T
    J Diabetes Investig; 2024 Jul; 15(7):843-850. PubMed ID: 38459768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study.
    Schleyer T; Hui S; Wang J; Zhang Z; Knapp K; Baker J; Chase M; Boggs R; Simpson RJ
    J Manag Care Spec Pharm; 2019 May; 25(5):544-554. PubMed ID: 31039062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virus.
    Burkholder GA; Muntner P; Zhao H; Mugavero MJ; Overton ET; Kilgore M; Drozd DR; Crane HM; Moore RD; Mathews WC; Geng E; Boswell S; Floris-Moore M; Rosenson RS
    J Clin Lipidol; 2018; 12(4):988-998.e5. PubMed ID: 29853312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment.
    Leibowitz M; Karpati T; Cohen-Stavi CJ; Feldman BS; Hoshen M; Bitterman H; Suissa S; Balicer RD
    JAMA Intern Med; 2016 Aug; 176(8):1105-13. PubMed ID: 27322095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.
    Mann D; Reynolds K; Smith D; Muntner P
    Ann Pharmacother; 2008 Sep; 42(9):1208-15. PubMed ID: 18648016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of on-Statin Lipid and Lipoprotein Levels for the Prediction of First Cardiovascular Event in Type 2 Diabetes Mellitus.
    Kim JY; Choi J; Kim SG; Kim NH
    Diabetes Metab J; 2023 Nov; 47(6):837-845. PubMed ID: 37915183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy.
    Ndrepepa G; Braun S; Tada T; Guerra E; Schunkert H; Laugwitz KL; Kastrati A
    Cardiovasc Revasc Med; 2014 Apr; 15(3):131-6. PubMed ID: 24630704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of different statin therapy to change low-density lipoprotein cholesterol and high-density lipoprotein cholesterol level in Korean patients with and without diabetes.
    Khang AR; Song YS; Kim KM; Moon JH; Lim S; Park KS; Jang HC; Choi SH
    J Clin Lipidol; 2016; 10(3):528-537.e3. PubMed ID: 27206940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.
    Wong ND; Young D; Zhao Y; Nguyen H; Caballes J; Khan I; Sanchez RJ
    J Clin Lipidol; 2016; 10(5):1109-18. PubMed ID: 27678427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between persistence with statin therapy and reduction in low-density lipoprotein cholesterol level: analysis of real-life data from community settings.
    Shalev V; Goldshtein I; Halpern Y; Chodick G
    Pharmacotherapy; 2014 Jan; 34(1):1-8. PubMed ID: 23836549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort.
    Oni-Orisan A; Hoffmann TJ; Ranatunga D; Medina MW; Jorgenson E; Schaefer C; Krauss RM; Iribarren C; Risch N
    Circ Genom Precis Med; 2018 Sep; 11(9):e002043. PubMed ID: 30354326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.
    Natsuaki M; Furukawa Y; Morimoto T; Nakagawa Y; Ono K; Kaburagi S; Inada T; Mitsuoka H; Taniguchi R; Nakano A; Kita T; Sakata R; Kimura T;
    Circ J; 2012; 76(6):1369-79. PubMed ID: 22447012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.